Transitional Cell Carcinoma Completed Phase 2 / 3 Trials for Rogaratinib (DB15078)

Also known as: Carcinoma, Transitional Cell / Carcinoma transitional cell / Transitional cell carcinoma (morphologic abnormality)

IndicationStatusPhase
DBCOND0031000 (Transitional Cell Carcinoma)Completed2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03410693Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial CarcinomaTreatment